Why Sobi’s EMPAVELI approval in Canada may change the rare kidney disease treatment landscape
Health Canada clears EMPAVELI for C3G and IC-MPGN. Read what this changes for nephrology treatment, market access, and rare kidney disease care.
ENYO Pharma’s vonafexor reverses kidney decline in Alport syndrome with sustained benefit
Vonafexor reversed kidney decline in Alport syndrome patients. Find out what ENYO Pharma’s Phase 2 results could mean for FXR drugs and kidney care.
Inside Insilico Medicine’s CKD push: AI-driven ISM4808 heads to Greater China with TaiGen
Insilico Medicine has licensed its AI-discovered oral PHD inhibitor ISM4808 to TaiGen Biotechnology for exclusive development and commercialization in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan. The deal follows Investigational New Drug clearance in China in 2023 and positions TaiGen to bring the asset into clinical trials targeting anemia associated […]
Will Aspaveli reshape rare kidney disease treatment in Europe? CHMP greenlight sets regulatory milestone
Swedish Orphan Biovitrum AB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Aspaveli, the pegcetacoplan-based therapy developed in partnership with Apellis Pharmaceuticals Inc., for the treatment of C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. The recommendation covers use in patients aged 12 years and older […]